TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07457671: A Phase 2a Exploratory Study of TAR-0520 Gel in Prevention of Hand and Foot Syndrome

Sponsor: Tarian Pharma · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 25 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,714,400

Rescue Site Savings

+$3,120,800

Unlock Full NCT07457671 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07457671 Rescue Dossier →